The study focuses on Drug and Therapeutics Committees, or DTCs, multidisciplinary groups typically made up of physicians, pharmacists, nurses and healthcare administrators. Their traditional role is to promote the “rational use” of medicines: giving patients drugs appropriate to their medical needs, at individually suitable doses, for long enough to work, and at the lowest reasonable cost. In Sweden, every one of the country’s 21 regions is required to have at least one such committee. These bodies develop formularies, advise policymakers and clinicians, analyze prescribing data and organize professional education across hospitals and primary-care centers. The new analysis argues that rational prescribing must now include a further consideration: the connection between human health, animals, plants and the shared environment.

That connection is increasingly difficult to ignore. Many active pharmaceutical ingredients are biologically potent by design, and some remain chemically stable after excretion. Conventional wastewater treatment can remove a proportion of these compounds, but not all of them. Residues may therefore reach aquatic ecosystems at concentrations capable of affecting sensitive organisms, particularly when exposure is continuous. Diclofenac, a widely used nonsteroidal anti-inflammatory drug, has become an emblematic example. The drug caused catastrophic declines in vulture populations in South Asia when birds fed on the carcasses of treated livestock and developed fatal kidney failure. Laboratory and field studies have also linked diclofenac exposure to damage in fish tissues, including the liver, kidneys and gills. Swedish authorities classify diclofenac and ciprofloxacin as river-basin-specific pollutants, while several hormones, including estradiol and ethinylestradiol, are also recognized as water contaminants.

The second environmental threat examined in the study comes from fluoroquinolone antibiotics, particularly ciprofloxacin and norfloxacin. These drugs can be persistent in aquatic environments and may exert antibacterial effects far below the concentrations used to treat patients. That matters because low-level antibiotic exposure can create evolutionary pressure favoring resistant bacteria. In effect, wastewater containing pharmaceutical residues may act as a diffuse training ground for microbes, selecting genetic variants able to survive future treatments. Fluoroquinolones also carry important clinical warnings. European regulators have restricted their use because of potentially disabling and long-lasting effects involving connective tissue, including tendon damage and increased risks associated with aortic complications. Unlike diclofenac, however, ciprofloxacin remains essential for some serious infections, including certain upper urinary-tract infections accompanied by fever. The goal is therefore not simple elimination, but precise, evidence-based use.

Researchers conducted an observational case study using official reports, regional and national agency websites, educational materials, communications, presentations and other documents published between 1988 and 2024. They reconstructed how the two DTCs developed environmental policies and compared those activities with sales data for diclofenac, ciprofloxacin and norfloxacin. Prescription and over-the-counter sales were obtained from the Swedish eHealth Agency and converted into kilograms of active substance per year. For systemic diclofenac, the analysis included tablets and capsules; topical products such as gels were assessed separately. Fluoroquinolone calculations covered the two products that were available in Sweden during the period. Measuring mass rather than simply counting prescriptions provides a closer approximation of the amount of pharmaceutical material entering the environment, although it still does not reveal how much was actually consumed or improperly discarded.

Gävleborg began considering the environmental consequences of medicines after a regional political decision in 2002. Over time, the policy became embedded in the region’s formulary, the list of medicines recommended to prescribers. Since 2019, the formulary has included environmental information for every listed drug when such information is available, and medicines with lower environmental impact may be favored when effectiveness, safety and cost-effectiveness are otherwise comparable. The guidance also identifies situations in which non-drug approaches could replace medication. Diclofenac received an explicit “anti-recommendation” in 2018, reflecting both its cardiovascular risks and its ecological effects. The committee also monitored prescribing by individual healthcare centers and hospital clinics, returned the results to clinicians and managers, and used comparisons between providers to encourage improvement.

Västernorrland took a similarly broad approach, beginning environmental work when its DTC was formed in 1997 and creating a dedicated “Pharmaceuticals and Environment” task force in 2021. Its measures included encouraging smaller starter packs for long-term therapies, reassessing treatments when benefits no longer outweighed risks, conducting medication reviews for older patients and promoting the return of unused medicines to pharmacies rather than flushing them into wastewater or placing them in household waste. The regional formulary emphasizes non-pharmacological alternatives such as cognitive behavioral therapy for some mental-health conditions and physiotherapy for some forms of pain. Environmental requirements have also been incorporated into medicine procurement, and the committee works with pharmacies, water and wastewater organizations and healthcare payers. Environmental representatives at healthcare providers receive specialized training, supported by a digital education course.

The prescribing data reveal substantial changes over the 25-year period. Systemic diclofenac sales rose during the first two decades and reached approximately 127 kilograms in Gävleborg and 137 kilograms in Västernorrland in 2011. They then declined rapidly. Over-the-counter systemic sales remained near 20 kilograms per year until 2020, when oral diclofenac was reclassified as prescription-only in Sweden because of cardiovascular concerns. The change did not produce a marked compensatory surge in topical diclofenac sales in either region. Topical products, introduced in 2005, increased for several years, particularly through over-the-counter channels, but their use also began to fall after 2016. The researchers caution that the trends cannot be attributed to the DTCs alone: national regulation, professional campaigns and changes in public awareness also influenced prescribing.

Fluoroquinolone use followed a different trajectory. In 2000, roughly 37 to 50 kilograms each of ciprofloxacin and norfloxacin were sold in each region. Norfloxacin use declined steadily until the product was removed from the Swedish market in 2020. Ciprofloxacin use initially increased as norfloxacin declined, then began falling after 2012, with an especially low level during the COVID-19 pandemic. Gävleborg introduced a fluoroquinolone prescribing target in 2003, while Västernorrland followed in 2005. The latter eventually specified that no more than 10 percent of urinary-tract-infection antibiotic prescriptions for women in primary care should be fluoroquinolones. Gävleborg set a target of fewer than five defined daily doses per 1,000 listed patients per day in primary care. These targets do not prohibit clinically justified treatment; they are intended to make unnecessary prescribing visible and reduce it.

The researchers say the Swedish experience offers a template for healthcare systems facing the same dilemma: how to preserve access to effective medicines while limiting their unintended ecological consequences. The approach begins with a technical challenge that remains unresolved—environmental information is missing for many active pharmaceutical ingredients. Reliable data on persistence, toxicity, bioaccumulation and effects on aquatic species are needed before committees can compare drugs meaningfully, and information about pollution from manufacturing is often absent even when risks from use have been assessed. Better environmental data could allow regulators and DTCs to distinguish drugs that are readily degraded from those that persist, accumulate or disrupt biological processes. Upstream decisions are especially important because wastewater treatment improvements, although necessary, cannot fully compensate for excessive or inappropriate use. The study does not prove that regional policies caused every observed decline, and sales do not equal consumption: medicines may remain unused in homes or be discarded incorrectly. Even so, it demonstrates how environmental stewardship can become part of everyday clinical decision-making, turning a prescription from a purely medical transaction into a One Health decision with consequences beyond the patient.

Neonatal Nurse Practitioners undergo rigorous advanced training that builds on their foundational bedside experience in neonatal nursing. This progression is vital in equipping them with the skills to conduct comprehensive patient assessments, manage complex clinical scenarios, and implement therapeutic regimens efficiently. Unlike traditional nursing roles, NNPs often take on responsibilities traditionally reserved for physicians, such as ordering and interpreting diagnostic tests, developing management plans, and responding to neonatal emergencies. The depth of their specialized knowledge allows them to optimize neonatal outcomes, especially in high-acuity environments like Neonatal Intensive Care Units (NICUs), where seconds can mean the difference between life and death.

The presence of NNPs is most pronounced in acute care settings, where they are pivotal in managing critically ill infants. NICUs of various designations—ranging from Level II to Level IV—rely heavily on the clinical acumen and procedural competencies of NNPs. Their roles extend beyond clinical care to include parent education, interdisciplinary collaboration, and quality improvement initiatives. In Newborn Nurseries and delivery facilities, NNPs serve as frontline responders to immediate neonatal complications, bridging gaps between nursing staff and neonatologists. This versatility not only enhances team dynamics but also ensures continuity of care during the most delicate initial stages of neonatal adaptation to extrauterine life.

Despite their integral position, NNPs face significant challenges related to role clarity and institutional support. Ambiguity in professional boundaries occasionally leads to underutilization or conflict within healthcare teams. Many institutions lack formal policies that fully integrate NNPs into neonatal care pathways or provide them with authority commensurate to their training. Bridging this gap requires deliberate advocacy and policy reform aimed at recognizing NNPs as autonomous clinicians with unique contributions. Moreover, fostering collaborative environments where physician-practitioner relationships are founded on mutual respect and shared goals is essential for optimizing care delivery.

Examining real-world cases illuminates the transformative potential of NNPs. One illustrative scenario involves a critically ill preterm infant presenting with respiratory distress syndrome in a tertiary NICU. Here, the NNP swiftly performed an in-depth neonatal assessment, initiated surfactant therapy, and coordinated respiratory support, all while effectively communicating with the pediatric intensivist and family members. This integrated approach not only stabilized the infant but also reduced futile interventions, demonstrating how NNP-led evidence-based care can significantly improve neonatal morbidity and mortality outcomes.

Collaboration between neonatologists and NNPs emerges as a cornerstone for advancing neonatal health. The complementary expertise of the two professional groups fosters a richer clinical perspective, enabling nuanced decision-making that accounts for both physiological complexity and the nuances of patient-family interactions. Such interdisciplinary partnerships are particularly vital in navigating the complexities of neonatal pharmacotherapy, nutritional management, and long-term developmental planning, areas where research continues to redefine best practices.

Advances in neonatal care, including cutting-edge technology and evolving clinical protocols, mandate that NNPs remain continuously engaged in professional development. Their role as knowledge brokers within neonatal teams underscores the importance of ongoing education and training. Integration of simulation-based learning, telemedicine, and data-driven quality metrics has significantly enhanced the ability of NNPs to respond to emergent clinical challenges with agility and accuracy, underlining their dynamic role in neonatal care ecosystems.

Healthcare policies must evolve to accommodate and empower NNPs effectively. Regulatory frameworks that delineate scope of practice, credentialing processes, and reimbursement structures are crucial to sustaining the growth of NNP roles. Encouraging institutions to adopt inclusive policies that recognize NNPs’ capabilities will facilitate broader implementation of standardized care protocols and reduce variability in neonatal treatment. Such reforms could also improve workforce retention, addressing the pressing issue of neonatal nursing shortages worldwide.

The economic implications of integrating NNPs into neonatal care merit serious consideration. Numerous studies indicate that utilizing NNPs as part of the care team can lead to cost savings by reducing hospital length of stay, minimizing unnecessary diagnostic testing, and preventing complications through proactive management. This cost-effectiveness does not compromise—rather, it enhances—quality of care, marking NNPs as uniquely positioned to contribute to value-based healthcare models that prioritize outcomes alongside fiscal responsibility.

Parental involvement and education constitute another pivotal area where NNPs exert profound influence. Their accessible communication style and specialized training enable them to guide families through complex neonatal care trajectories, providing emotional support and facilitating informed decision-making. This relational aspect of their role is essential in fostering trust and engagement, which are well-documented determinants of improved neonatal outcomes.

In addition to clinical expertise, NNPs often serve as advocates for vulnerable populations, addressing social determinants of health that impact neonatal well-being. By coordinating with social workers, public health entities, and community resources, NNPs contribute to a holistic approach to neonatal care that transcends immediate hospitalization. This advocacy is particularly critical in underserved communities where disparities in healthcare access and outcomes disproportionately affect neonates.

The future of neonatal care will undoubtedly be shaped by innovations in artificial intelligence, genomics, and personalized medicine, areas where NNPs have a vital role to play in translating scientific advances into bedside practice. Their unique position allows them to integrate complex data with clinical intuition, tailoring interventions to individual infants’ needs and advancing precision neonatal care.

Recognition of NNPs as essential contributors requires a cultural shift within healthcare organizations and professional spheres. By fostering awareness of their competencies and outcomes, healthcare systems can build more cohesive teams that leverage diverse expertise. Celebrating successes and disseminating research on NNP-led interventions will drive this change, encouraging more institutions to formalize and expand NNP roles.

As highlighted by recent scholarship, clarifying the scope and impact of NNPs facilitates improved physician-practitioner dynamics. When roles are clearly defined and respected, collaborative decision-making becomes more efficient and less prone to conflict. This synergy translates into better clinical pathways, faster responsiveness to neonatal emergencies, and ultimately, enhanced survival and quality of life for newborns.

The imperative to advocate for NNPs extends beyond clinical settings into academic and policy-making arenas. By engaging in research, policy dialogue, and professional networks, NNPs can shape the trajectory of neonatal care standards and workforce development. Supporting their leadership in these domains will contribute to sustainable improvements in neonatal health systems globally.

In conclusion, the Neonatal Nurse Practitioner is a pivotal yet underrecognized player in the future of neonatal intensive care. As healthcare continues to prioritize interdisciplinary collaboration and evidence-based practice, acknowledging and investing in the NNP role promises to elevate care quality, reduce neonatal morbidity and mortality, and optimize resource utilization. The challenge ahead lies in revising policies, enhancing education, and nurturing collaborative cultures that empower NNPs to fulfill their full potential within neonatal care teams.

Subject of Research: The role and impact of Neonatal Nurse Practitioners (NNPs) in neonatal care

Article Title: Distinguishing the role of the neonatal nurse practitioner in neonatal care

Article References:
Hull, W.L., Jones, J., Bell, T. et al. Distinguishing the role of the neonatal nurse practitioner in neonatal care. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02489-6

Image Credits: AI Generated

DOI: 04 November 2025

In response to these challenges, an exciting new initiative has emerged—establishing integrated chronic non-communicable disease management clinics. These clinics represent a groundbreaking step forward in consolidating healthcare services specifically tailored to manage and treat NCDs. Through this integrative framework, healthcare professionals aim to enhance patient outcomes by providing coordinated care that encompasses prevention, diagnosis, treatment, and ongoing management of chronic conditions.

The foundation of these clinics lies in their holistic approach to patient care. By bringing together diverse healthcare professionals, including physicians, nurses, nutritionists, and mental health specialists, the clinics create a multidisciplinary environment fostering collaborative decision-making. This teamwork enables comprehensive treatment plans that address the multifaceted nature of chronic diseases, emphasizing the interconnectedness of physiological, psychological, and social factors.

Historically, chronic disease management in China has been fragmented, often leading to inefficiencies and suboptimal patient care. Many individuals with NCDs receive treatment from various providers, resulting in a lack of continuity and, ultimately, poorer health outcomes. The integrated model seeks to bridge these gaps by ensuring that patients receive seamless care throughout their treatment journey, minimizing the risk of miscommunication and redundancy.

One of the pivotal aspects of this initiative is the emphasis on preventive care. Preventing chronic diseases before they manifest is far more effective and less costly than managing them once diagnosed. Education and awareness programs form an integral part of the clinics’ strategy, empowering individuals with knowledge about risk factors, lifestyle changes, and early signs of potential health issues. These programs encourage proactive health-seeking behavior, which is essential in combating the rising tide of NCDs.

Moreover, technology plays an instrumental role in the operational framework of these management clinics. The integration of telemedicine solutions allows healthcare providers to monitor patients remotely, facilitating timely interventions without the need for physical visits. This is especially crucial in rural and underserved areas where access to specialized care may be limited. By harnessing technology, the clinics can ensure that patients remain engaged in their health management while reducing barriers to care.

In addition to improving patient outcomes, this integrated approach aims to alleviate pressures on the healthcare system. With chronic diseases accounting for a significant proportion of healthcare expenditures, streamlining the management processes can lead to more efficient resource utilization. By focusing on preventive care and early intervention, the clinics aspire to decrease hospitalization rates, thereby driving down overall costs associated with healthcare delivery.

Research indicates that integrated care models have demonstrated success in various international contexts, providing valuable insights for implementation in China. Countries like Sweden and the Netherlands have pioneered integrated care systems that effectively manage chronic diseases while improving patient satisfaction. Drawing from these experiences, China has the opportunity to tailor its model to address the specific sociocultural dynamics that influence health behaviors and healthcare access among its population.

It is essential to highlight that the success of these integrated clinics depends not only on healthcare providers but also on community support and government policy. Stakeholder engagement at multiple levels, including governmental agencies, non-governmental organizations, and local communities, is crucial for creating an ecosystem that supports chronic disease management. By fostering partnerships that align with the goals of these clinics, the initiative stands a better chance of achieving long-term sustainability and impact.

As the integrated chronic non-communicable disease management clinics take shape, ongoing research and evaluation will be integral to assess their effectiveness. Continuous monitoring of patient outcomes, cost-effectiveness, and patient satisfaction will provide insights into refining the operational model and expanding successful practices. Such data will not only aid in optimizing the clinics but will also inform policymakers about the broader implications of implementing integrated care systems across the country.

Recognizably, the fight against chronic diseases is not merely a healthcare issue but a societal challenge that requires collective action. As awareness grows regarding the ramifications of lifestyle choices on health, community engagement becomes paramount. The clinics can serve as a focal point for community initiatives, where individuals come together to share experiences, support one another, and work collectively towards healthier lifestyles. This sense of community can significantly enhance the overall impact of the management clinics, cultivating a culture that prioritizes health and wellness.

It is also important to recognize the potential for these integrated clinics to serve as a model for other countries experiencing similar health burdens. The lessons learned from China’s implementation can provide valuable insight for nations grappling with the complexities of chronic disease management. By showcasing effective strategies and outcomes, China can contribute to the broader global discourse on health management practices.

In conclusion, the establishment of integrated chronic non-communicable disease management clinics marks a pivotal shift in the way China approaches the looming health burden posed by NCDs. By focusing on a holistic, integrated model that emphasizes prevention and interdisciplinary collaboration, the initiative seeks to transform healthcare delivery for chronic conditions. With continued support, evaluation, and community engagement, these clinics have the potential to make substantial strides in improving population health and setting a precedent for sustainable healthcare practices both within China and globally.

Subject of Research: Integrated Chronic Non-Communicable Disease Management Clinics in China

Article Title: Establishing integrated chronic non-communicable disease management clinics to address China’s looming health burden.

Article References:
Tu, WJ., Zhang, X., Wang, HQ. et al. Establishing integrated chronic non-communicable disease management clinics to address China’s looming health burden. Military Med Res 12, 25 (2025). https://doi.org/10.1186/s40779-025-00616-0

Image Credits: AI Generated

DOI:

Keywords: Chronic diseases, healthcare management, integrated care, China, NCDs, prevention, telemedicine, healthcare systems.